All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @princessleahsfitforlife on TikTok · 181s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @princessleahsfitforlife's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hi everyone my five-month update is a little bit late
  2. 0:06It is due on the 19th of December, so here I am
  3. 0:11I've got the next couple of weeks of work, so I've got a couple of things planned for this account
  4. 0:16I'm gonna do a separate video on my update with a surgeon. That was the last time I spoke to you guys
  5. 0:23And I did say that I will give you an update but some
  6. 0:27Watch this space. It's coming soon. It's very exciting because it's happening a lot sooner than what I expected and I'm really
  7. 0:34Looking forward to getting you all the details about that
  8. 0:39So let's get to this month statistics. I am currently weighing in at 58.50
  9. 0:49Sorry 59.8 kilos, so that takes my total weight loss now to
  10. 0:5720.2 kilos, so 19th of July I started on success and I
  11. 1:03weighed 80 kilos and a couple of days ago when I weighed myself last like I said I was 59.8 kilos
  12. 1:12this month
  13. 1:14Comparatively to last month. I think I've lost about three kilos
  14. 1:18Definitely starting to slow down a lot, but obviously I
  15. 1:22Don't have anywhere near the amount of weight to use as what I did in the beginning
  16. 1:28Still not doing any exercise, but I certainly I'm planning on
  17. 1:32That is part of my new year
  18. 1:36Plan to start going back to the gym because before
  19. 1:39In a formal life, I guess I was definitely a gym girl
  20. 1:43I used to go to the gym a lot and I do get a lot of mental health benefits as well as physical benefits out there
  21. 1:49So alcohol update still off the alcohol taking it as a win when we're coming into this Christmas season
  22. 1:57Every now and then I think I'll have a glass of wine and I do take a couple of sips and I just
  23. 2:03Really stummy it's I don't know whether or not it's the taste of it sometimes it tends to give me a little bit of
  24. 2:09Free slots, which is annoying
  25. 2:12But yeah, the alcohol
  26. 2:16Is like the lack of alcohol I should say is going really well. I'm really proud of myself for that
  27. 2:23What else did I want to talk to you about side effects? I'm getting a lot of hair loss
  28. 2:28So if there's anyone out there that's looking at this video and they are on success and they've noticed something similar reach out
  29. 2:36I'd love to hear your experience again if you've got any questions
  30. 2:40Drop them in the comments below and in the next couple of weeks or I'm off all to my best to get back to you
  31. 2:47But yeah, I'm still going strong still really happy with where I'm going and I am in this extended journey for the long haul
  32. 2:54So I will see you soon and take care

Saxenda for weight loss: what the TikTok journey videos skip

Leah

TikTok creator

424.3K viewsWatch on TikTok

Quick answer

The creator reports 20.2kg of weight loss over five months on liraglutide (Saxenda) starting from 80kg, with no concurrent exercise programme. She is reporting hair shedding consistent with telogen effluvium secondary to rapid caloric restriction, and describes spontaneous reduction in alcohol consumption that aligns with emerging data on GLP-1 receptor agonists and reward-pathway modulation. No dosing information is disclosed, and no disease treatment claims are made.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Saxenda for weight loss: what the TikTok journey videos skip, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Saxenda for weight loss: what the TikTok journey videos skip should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Saxenda for weight loss: what the TikTok journey videos skip" from Leah. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports 20.

The reason this review is not generic is the source wording and the canonical claim label "glp1 saxendajourney saxendasuccess saxenda weightlossprogress sax." In this clip, the useful excerpt is: "Hi everyone my five-month update is a little bit late It is due on the 19th of December, so here I am I've got the next couple of weeks of work, so I've got a couple of things planned for this account I'm gonna do a separate video on my..." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Hair loss during GLP-1 treatment is most likely telogen effluvium from caloric restriction, not a direct drug effect.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator reports 20.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator reports 20.2kg of weight loss over five months on liraglutide (Saxenda) starting from 80kg, with no concurrent exercise programme. She is reporting hair shedding consistent with telogen effluvium secondary to rapid caloric restriction, and describes spontaneous reduction in alcohol consumption that aligns with emerging data on GLP-1 receptor agonists and reward-pathway modulation. No dosing information is disclosed, and no disease treatment claims are made.
  • The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed average liraglutide weight loss of 8.4kg over 56 weeks. Losing 20kg in five months is above average but not impossible, particularly when alcohol calories are also removed.
  • Hair loss during GLP-1 treatment is most likely telogen effluvium from caloric restriction, not a direct drug effect. Rebora (2021) confirmed rapid weight loss reliably triggers this within 2 to 4 months of the deficit starting.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed average liraglutide weight loss of 8.4kg over 56 weeks. Losing 20kg in five months is above average but not impossible, particularly when alcohol calories are also removed.
  • Hair loss during GLP-1 treatment is most likely telogen effluvium from caloric restriction, not a direct drug effect. Rebora (2021) confirmed rapid weight loss reliably triggers this within 2 to 4 months of the deficit starting.
  • GLP-1 receptor agonists may reduce alcohol cravings via dopamine pathway modulation (Leggio et al., 2023, JCI Insight), but this is preliminary research, not an established clinical use of liraglutide.
  • Tischler et al. (2022, Obesity Reviews) found 25 to 40 percent of total weight lost on GLP-1 drugs in exercise-free conditions was lean mass, not fat. This is a clinically significant issue for anyone planning post-weight-loss surgery.
  • Most people regain substantial weight within 12 months of stopping liraglutide. The SCALE Maintenance trial (Wadden et al., 2013, Obesity) showed regain began promptly after discontinuation, which is why ongoing use or transition planning matters.
  • Adequate protein intake (roughly 1.2g per kilogram body weight) during GLP-1-assisted weight loss can reduce telogen effluvium severity and help preserve lean mass, though this creator does not mention her diet composition.
  • Liraglutide is a daily injectable drug that requires dose titration. Anyone seeing this video and considering it should consult a regulated prescriber. Results shown here are one individual's experience under unknown clinical supervision.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @princessleahsfitforlife actually say?

Over five months on Saxenda (liraglutide), this creator reports dropping from 80kg to 59.8kg, a total loss of 20.2kg. She says weight loss is "definitely starting to slow down," she has done no exercise, she has stopped drinking alcohol, and she is now noticing significant hair loss. She frames the alcohol change as partly driven by the medication making wine taste unpleasant and causing what sounds like flushing episodes.

She is also hinting at an upcoming cosmetic procedure, likely related to the "mummymakeover" hashtag, which suggests excess skin removal following rapid weight loss. No specific dosing information is mentioned, and she makes no medical claims about liraglutide treating disease.

Does the science back this up?

The weight loss rate here is faster than average trial data, but not implausible given her starting point and the alcohol reduction. The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide 3mg produced mean weight loss of about 8.4kg over 56 weeks versus placebo. Twenty kilos in five months substantially exceeds that average, but trial participants were not necessarily also cutting alcohol calories.

On hair loss, she is likely experiencing telogen effluvium, a stress-related shedding triggered by rapid caloric restriction rather than by liraglutide itself. A 2021 review in the Journal of the American Academy of Dermatology (Rebora) confirmed that aggressive calorie deficits reliably trigger telogen effluvium within two to four months of the deficit beginning, which aligns exactly with her timeline. The hair loss is real, common, and almost certainly not a direct drug side effect.

The alcohol aversion observation is also scientifically plausible. GLP-1 receptor agonists appear to reduce reward-driven consumption. Preclinical and early human data (Leggio et al., 2023, JCI Insight) suggest GLP-1 signalling dampens dopaminergic reward responses to alcohol, which could explain why she now finds wine unpleasant rather than appealing.

What did they get wrong (or right)?

She got the hair loss observation right in the sense that it is real and documented. She got it slightly wrong by implying it might be Saxenda-specific. It is almost certainly caloric restriction doing that, not the drug molecule. Worth knowing the difference because it affects how you respond to it.

Her weight loss framing is honest. She does not overclaim. Saying it is "slowing down" at lower body weight is accurate physiology. Adaptive thermogenesis and reduced absolute body mass mean the same deficit produces slower results over time. She does not pretend the drug is magic, and she openly admits she has done zero exercise, which is a fair disclosure most influencers skip.

The alcohol angle is where things get interesting. She does not claim Saxenda is a treatment for alcohol use. She just describes her experience, which is the appropriate lane for a patient sharing a personal journey. That said, viewers should not interpret one person's reduced cravings as a reliable or universal effect. The clinical evidence for liraglutide specifically on alcohol is preliminary at best.

What should you actually know?

If you are considering Saxenda, a few things this video does not cover matter quite a bit. First, liraglutide requires daily subcutaneous injection at doses titrated up to 3mg. The SCALE trial data show most people regain significant weight within a year of stopping. That is not a reason to avoid it, but it is a reason to treat it as a long-term tool, not a five-month fix.

Second, the hair loss will almost certainly resolve on its own within six to nine months once the body adapts to the new weight, assuming nutrition is adequate. Protein intake below roughly 1.2g per kilogram of body weight accelerates telogen effluvium. If you are on a GLP-1 and losing hair, check your protein before panicking about the drug.

Third, the upcoming cosmetic surgery hint in the hashtags raises a real clinical point. Rapid weight loss, particularly without resistance training, causes disproportionate lean mass loss alongside fat. Tischler et al. (2022, Obesity Reviews) found GLP-1 users in several trials lost 25 to 40 percent of their total weight loss as lean mass rather than fat. That changes surgical risk profiles and recovery timelines. If you are planning a body contouring procedure after GLP-1-assisted weight loss, that conversation with a surgeon matters more than most people realise.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Leah · TikTok creator

424.3K views on this video

#saxendajourney #saxendasuccess #saxenda #weightlossprogress #saxendaweightlossjourney #weightlossmotivation #weightloss #alcoholfreejourney #CapCut #mummymakeoversurgery

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the scale trial (pi-sunyer et al., 2015, nejm) showed average?

The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed average liraglutide weight loss of 8.4kg over 56 weeks. Losing 20kg in five months is above average but not impossible, particularly when alcohol calories are also removed.

What does the video say about hair loss during glp-1 treatment?

Hair loss during GLP-1 treatment is most likely telogen effluvium from caloric restriction, not a direct drug effect. Rebora (2021) confirmed rapid weight loss reliably triggers this within 2 to 4 months of the deficit starting.

What does the video say about glp-1 receptor agonists may reduce alcohol cravings via dopamine pathway?

GLP-1 receptor agonists may reduce alcohol cravings via dopamine pathway modulation (Leggio et al., 2023, JCI Insight), but this is preliminary research, not an established clinical use of liraglutide.

What does the video say about tischler et al. (2022, obesity reviews) found 25 to 40?

Tischler et al. (2022, Obesity Reviews) found 25 to 40 percent of total weight lost on GLP-1 drugs in exercise-free conditions was lean mass, not fat. This is a clinically significant issue for anyone planning post-weight-loss surgery.

What does the video say about most people regain substantial weight within 12 months of stopping?

Most people regain substantial weight within 12 months of stopping liraglutide. The SCALE Maintenance trial (Wadden et al., 2013, Obesity) showed regain began promptly after discontinuation, which is why ongoing use or transition planning matters.

What does the video say about adequate protein intake (roughly 1.2g per kilogram body weight) during?

Adequate protein intake (roughly 1.2g per kilogram body weight) during GLP-1-assisted weight loss can reduce telogen effluvium severity and help preserve lean mass, though this creator does not mention her diet composition.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Leah, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.